Cargando…
Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up
Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hosp...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864433/ https://www.ncbi.nlm.nih.gov/pubmed/36679853 http://dx.doi.org/10.3390/vaccines11010008 |
_version_ | 1784875583341068288 |
---|---|
author | Sansone, Emanuele Bonfanti, Carlo Sala, Emma Renzetti, Stefano Terlenghi, Luigina Matteelli, Alberto Tiraboschi, Mara Maria Pedrazzi, Tatiana Lombardo, Massimo Rossi, Camillo Indelicato, Anna Maria Caruso, Arnaldo De Palma, Giuseppe |
author_facet | Sansone, Emanuele Bonfanti, Carlo Sala, Emma Renzetti, Stefano Terlenghi, Luigina Matteelli, Alberto Tiraboschi, Mara Maria Pedrazzi, Tatiana Lombardo, Massimo Rossi, Camillo Indelicato, Anna Maria Caruso, Arnaldo De Palma, Giuseppe |
author_sort | Sansone, Emanuele |
collection | PubMed |
description | Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration. |
format | Online Article Text |
id | pubmed-9864433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98644332023-01-22 Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up Sansone, Emanuele Bonfanti, Carlo Sala, Emma Renzetti, Stefano Terlenghi, Luigina Matteelli, Alberto Tiraboschi, Mara Maria Pedrazzi, Tatiana Lombardo, Massimo Rossi, Camillo Indelicato, Anna Maria Caruso, Arnaldo De Palma, Giuseppe Vaccines (Basel) Article Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration. MDPI 2022-12-20 /pmc/articles/PMC9864433/ /pubmed/36679853 http://dx.doi.org/10.3390/vaccines11010008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sansone, Emanuele Bonfanti, Carlo Sala, Emma Renzetti, Stefano Terlenghi, Luigina Matteelli, Alberto Tiraboschi, Mara Maria Pedrazzi, Tatiana Lombardo, Massimo Rossi, Camillo Indelicato, Anna Maria Caruso, Arnaldo De Palma, Giuseppe Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title | Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title_full | Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title_fullStr | Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title_full_unstemmed | Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title_short | Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up |
title_sort | immune responses to sars-cov-2 infection and vaccine in a big italian covid-19 hospital: an 18-month follow-up |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864433/ https://www.ncbi.nlm.nih.gov/pubmed/36679853 http://dx.doi.org/10.3390/vaccines11010008 |
work_keys_str_mv | AT sansoneemanuele immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT bonfanticarlo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT salaemma immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT renzettistefano immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT terlenghiluigina immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT matteellialberto immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT tiraboschimaramaria immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT pedrazzitatiana immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT lombardomassimo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT rossicamillo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT indelicatoannamaria immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT carusoarnaldo immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup AT depalmagiuseppe immuneresponsestosarscov2infectionandvaccineinabigitaliancovid19hospitalan18monthfollowup |